Envestnet Asset Management Inc. sells 5,128 shares of Bicycle Therapeutics plc (NASDAQ: BCYC)


Envestnet Asset Management Inc. trimmed its position in Bicycle Therapeutics plc (NASDAQ: BCYC – Get Rating) by 12.4% in Q1, according to its latest SEC filing. The company held 36,164 shares of the company after selling 5,128 shares during the period. Envestnet Asset Management Inc. owned 0.12% of Bicycle Therapeutics worth $1,587,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently changed their positions in the company. DekaBank Deutsche Girozentrale increased its position in Bicycle Therapeutics shares by 10.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the company valued at $562,000 after acquiring an additional 1,200 shares in the last quarter. Difesa Capital Management LP bought a new position in Bicycle Therapeutics during the fourth quarter worth approximately $213,000. Claro Advisors LLC purchased a new stake in shares of Bicycle Therapeutics in the fourth quarter for a value of approximately $221,000. Twelve Points Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth approximately $432,000. Finally, Soleus Capital Management LP bought a new position in shares of Bicycle Therapeutics during Q4 valued at approximately $624,000. Institutional investors hold 71.99% of the company’s shares.

Cycling Therapeutics Price Performance

NASDAQ: BCYC opened at $26.67 on Friday. The stock has a market capitalization of $791.57 million, a PE ratio of -8.74 and a beta of 0.76. Bicycle Therapeutics plc has a 1-year low of $12.08 and a 1-year high of $62.08. The company has a fifty-day simple moving average of $20.71 and a 200-day simple moving average of $28.50. The company has a current ratio of 9.88, a quick ratio of 9.88 and a debt ratio of 0.10.

Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) last reported quarterly earnings data on Thursday, August 4. The company reported ($0.90) EPS for the quarter, missing analyst consensus estimates of ($0.85) by ($0.05). Bicycle Therapeutics had a negative net margin of 533.03% and a negative return on equity of 30.07%. On average, research analysts expect Bicycle Therapeutics plc to post -3.73 EPS for the current financial year.

Wall Street analysts predict growth

Several analysts have commented on BCYC shares. Canaccord Genuity Group restated a “buy” rating and set a target price of $60.00 on shares of Bicycle Therapeutics in a Wednesday, July 6 report. Barclays assumed coverage for Bicycle Therapeutics shares in a Thursday, July 28 research report. They issued an “overweight” rating and a price target of $30.00 on the stock. SVB Leerink cut its price target on shares of Bicycle Therapeutics from $69.00 to $48.00 and set an “outperform” rating for the company in a Friday, Aug. 5 research note. JMP Securities reissued a “buy” rating and issued a $70.00 price target on shares of Bicycle Therapeutics in a research note on Monday, June 6. Finally, Piper Sandler reduced her price target on Bicycle Therapeutics from $76.00 to $37.00 and set an “overweight” rating for the company in a Monday, May 23 research report. Two analysts rated the stock with a hold rating and eleven gave the stock a buy rating. According to MarketBeat, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $56.92.

Bicycle Therapeutics Company Profile

(Get a rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin (BTC) conjugate, which is in Phase I/IIa clinical trials targeting tumors that express membrane matrix metalloprotease type 1.

See also

Institutional ownership by quarter for Bicycle Therapeutics (NASDAQ: BCYC)



Get news and reviews for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.